{"sentence_labels": [1, -1, -1, -1, -1], "text": "Patients were block-randomized between rFVIII and pdFVIII. The recombinant products included: Recombinate (Baxalta, Bannockburn, IL), Kogenate FS (Bayer AG, Leverkusen, Germany), Advate (Baxalta), and ReFacto AF (Pfizer, New York, NY). pdFVIII brands were Alphanate and Fanhdi (Grifols, Barcelona, Spain), Emoclot (Kedrion Biopharma, Lucca, Italy), and Factane (LFB, Les Ulis, France). Patients were followed for 50 consecutive exposure days or 3 years, until death, or until the development of a centrally confirmed inhibitor, whichever occurred first. An exposure day was defined as a calendar day with 1 or more infusions of FVIII.", "section": "\u00a9 2017 by The American Society of Hematology", "classification_label": 0, "section_number": 5, "sentences": ["Patients were block-randomized between rFVIII and pdFVIII.", "The recombinant products included: Recombinate (Baxalta, Bannockburn, IL), Kogenate FS (Bayer AG, Leverkusen, Germany), Advate (Baxalta), and ReFacto AF (Pfizer, New York, NY).", "pdFVIII brands were Alphanate and Fanhdi (Grifols, Barcelona, Spain), Emoclot (Kedrion Biopharma, Lucca, Italy), and Factane (LFB, Les Ulis, France).", "Patients were followed for 50 consecutive exposure days or 3 years, until death, or until the development of a centrally confirmed inhibitor, whichever occurred first.", "An exposure day was defined as a calendar day with 1 or more infusions of FVIII."], "doc_id": "39157"}